title: Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
abstract: OBJECTIVE
  To examine the safety and efficacy of 5-year administration of certolizumab pegol (CZP)+methotrexate (MTX) in patients with active rheumatoid arthritis (RA).
  
  
  METHODS
  Eligible patients from the Rheumatoid Arthritis Prevention of Structural Damage (RAPID)1 randomised controlled trial (RCT) were treated in open-label extension (OLE) with CZP 400 mg every other week (Q2W), reduced to 200 mg Q2W after ≥6 months, +MTX. Combined safety data from RCT and OLE are presented from initiation of CZP treatment to 12 wks post last visit in patients receiving ≥1 dose of CZP (Safety population, N=958). Efficacy data are presented to start of first site closure (wk 256 of CZP treatment: 52 wks in RCT+204 wks in OLE) for all patients randomised to receive CZP (intent-to-treat (ITT) population, N=783) and CZP patients who completed the 52 wk RCT and enrolled into OLE (wk 52 CZP completers, N=508). Disease Activity Score (DAS)28 (Erythrocyte Sedimentation Rate (ESR)), American College of Rheumatology Criteria (ACR) 20/50/70, Health Assessment Questionnaire - Disability Index (HAQ-DI), and patient retention (Kaplan-Meier analysis) were assessed.
  
  
  RESULTS
  Overall event rate per 100 patient-years (ER) of adverse events (AEs) was 290.4, most frequently: urinary tract infections (ER=7.9), nasopharyngitis (ER=7.3) and upper respiratory tract infections (ER=7.3). ER of serious AEs was 20.3 (infections=5.9, malignancies=1.2). 21 patients (2.2%) experienced an AE resulting in death (incidence rate=0.6). At wk 256 of treatment, 55.3% of the CZP ITT population were estimated to remain on treatment (68.7% if solely withdrawals due to AE or lack of efficacy were considered). In wk 52 CZP completers and CZP ITT population, DAS28 (ESR) remission rates and improvements from baseline were sustained to wk 256.
  
  
  CONCLUSIONS
  CZP+MTX treatment provided a favourable risk-benefit profile over 5 years in patients with active RA. No new safety signals were identified.
authors.affiliation: University of Toronto, Toronto, Canada.
authors.forename: Edward
authors.initials: E
authors.lastname: Keystone
authors.affiliation: Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, The Netherlands.
authors.forename: Robert
authors.initials: R
authors.lastname: Landewé
authors.affiliation: Karolinska Institute, Stockholm, Sweden.
authors.forename: Ronald
authors.initials: R
authors.lastname: van Vollenhoven
authors.affiliation: Montpellier University Hospital, Montpellier, France.
authors.forename: Bernard
authors.initials: B
authors.lastname: Combe
authors.affiliation: Stanford University, Palo Alto, California, USA.
authors.forename: Vibeke
authors.initials: V
authors.lastname: Strand
authors.affiliation: Swedish Medical Center and University of Washington, Seattle, Washington, USA.
authors.forename: Philip
authors.initials: P
authors.lastname: Mease
authors.affiliation: UCB Pharma, Raleigh, North Carolina, USA.
authors.forename: Laura
authors.initials: L
authors.lastname: Shaughnessy
authors.affiliation: UCB Pharma, Raleigh, North Carolina, USA.
authors.forename: Brenda
authors.initials: B
authors.lastname: VanLunen
authors.affiliation: Leiden University Medical Center, Leiden, The Netherlands.
authors.forename: Désirée
authors.initials: D
authors.lastname: van der Heijde
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068582:Certolizumab Pegol; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D010612:Pharyngitis / Q000276:immunology; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000276:immunology; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000276:immunology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D007166:Immunosuppressive Agents; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol; D008727:Methotrexate
keywords: Anti-TNF; DMARDs (biologic); Rheumatoid Arthritis
references.citation: Rheumatology (Oxford). 2012 Sep;51(9):1628-38
references.pmid: 22596211
references.citation: J Am Acad Dermatol. 2013 Jan;68(1):57-63
references.pmid: 22846689
references.citation: Lancet. 2008 Aug 2;372(9636):375-82
references.pmid: 18635256
references.citation: Arthritis Rheum. 2003 Jan;48(1):35-45
references.pmid: 12528101
references.citation: Arthritis Care Res (Hoboken). 2011 Mar;63(3):373-82
references.pmid: 20957659
references.citation: Arthritis Rheum. 2003 Jun;48(6):1513-20
references.pmid: 12794818
references.citation: Arthritis Rheum. 1996 Jan;39(1):34-40
references.pmid: 8546736
references.citation: Arthritis Rheum. 2006 Apr;54(4):1063-74
references.pmid: 16572441
references.citation: Arthritis Rheum. 1988 Mar;31(3):315-24
references.pmid: 3358796
references.citation: Ann Rheum Dis. 2012 Oct;71(10):1671-9
references.pmid: 22459542
references.citation: Ann Rheum Dis. 2009 Jun;68(6):797-804
references.pmid: 19015207
references.citation: Ann Rheum Dis. 2006 Jun;65(6):753-9
references.pmid: 16308341
references.citation: Arthritis Rheum. 2008 Nov;58(11):3319-29
references.pmid: 18975346
references.citation: Ann Rheum Dis. 2011 Mar;70(3):404-13
references.pmid: 21292833
references.citation: Curr Med Res Opin. 2008 Jul;24(7):2001-8
references.pmid: 18534049
references.citation: Arthritis Res Ther. 2009;11(6):R170
references.pmid: 19909548
references.citation: Ann Rheum Dis. 2011 Jun;70(6):886-90
references.pmid: 21378403
references.citation: J Rheumatol. 2012 Aug;39(8):1546-54
references.pmid: 22798265
references.citation: Arthritis Rheum. 2002 Jun;46(6):1443-50
references.pmid: 12115173
references.citation: Ann Intern Med. 1999 Mar 16;130(6):478-86
references.pmid: 10075615
references.citation: Ann Rheum Dis. 2009 Oct;68(10):1580-4
references.pmid: 19019888
references.citation: Arthritis Rheum. 2005 Jan;52(1):49-60
references.pmid: 15641062